| 2389 | Humans |
| 1640 | Male |
| 1527 | Female |
| 1206 | Nervous system diseases |
| 1181 | Middle Aged |
| 1085 | Aged |
| 924 | Parkinson disease |
| 831 | Adult |
| 705 | Parkinson's disease |
| 678 | Human |
| 361 | Aged, 80 and over |
| 342 | Treatment |
| 337 | Severity of Illness Index |
| 329 | Parkinson Disease (drug therapy) |
| 268 | Dystonia |
| 246 | Parkinson Disease (physiopathology) |
| 238 | Parkinson Disease (diagnosis) |
| 236 | Parkinson Disease (complications) |
| 235 | Case study |
| 215 | Tremor |
| 215 | Adolescent |
| 206 | Treatment Outcome |
| 204 | Animals |
| 197 | Antiparkinson Agents (therapeutic use) |
| 195 | Chemotherapy |
| 187 | Neurologic Examination |
| 171 | Parkinson Disease (genetics) |
| 170 | Parkinsonism |
| 169 | Parkinson Disease (epidemiology) |
| 162 | Levodopa (therapeutic use) |
| 161 | Magnetic Resonance Imaging |
| 152 | Dose-Response Relationship, Drug |
| 151 | Child |
| 146 | Diagnosis, Differential |
| 144 | Neuropsychological Tests |
| 137 | Brain (pathology) |
| 136 | Risk Factors |
| 136 | Retrospective Studies |
| 136 | Follow-Up Studies |
| 135 | Levodopa |
| 135 | Exploration |
| 133 | Double-Blind Method |
| 127 | Parkinson Disease (pathology) |
| 127 | Antiparkinson Agents (adverse effects) |
| 125 | Parkinson Disease (therapy) |
| 118 | Levodopa (adverse effects) |
| 112 | Parkinson Disease (psychology) |
| 111 | Case-Control Studies |
| 109 | Questionnaires |
| 105 | Disability Evaluation |
| 104 | Disease Progression |
| 103 | Electromyography |
| 102 | Time Factors |
| 102 | Dyskinesia |
| 98 | Reproducibility of Results |
| 97 | Neurologic Examination (drug effects) |
| 96 | Diagnosis |
| 96 | Complication |
| 93 | dystonia |
| 92 | Genotype |
| 88 | Huntington disease |
| 88 | Epidemiology |
| 87 | Age of Onset |
| 85 | Young Adult |
| 85 | Videotape Recording |
| 82 | essential tremor |
| 82 | Phenotype |
| 81 | Dystonia (diagnosis) |
| 80 | Drug Therapy, Combination |
| 79 | Risk factor |
| 79 | Mutation |
| 78 | Comparative study |
| 75 | Prevalence |
| 75 | Antiparkinson agent |
| 74 | Myoclonus |
| 74 | Deep brain stimulation |
| 71 | Drug Administration Schedule |
| 70 | Deep Brain Stimulation (methods) |
| 68 | Cohort Studies |
| 67 | Toxicity |
| 67 | Parkinson Disease (etiology) |
| 67 | Disease Models, Animal |
| 67 | Depression |
| 65 | Child, Preschool |
| 65 | Analysis of Variance |
| 65 | Age Factors |
| 64 | deep brain stimulation |
| 64 | Tremor (diagnosis) |
| 63 | Cognition Disorders (etiology) |
| 61 | Symptomatology |
| 61 | Dementia |
| 60 | Dopamine |
| 60 | Brain Mapping |
| 60 | Antiparkinson Agents (administration & dosage) |
| 59 | Parkinson Disease (metabolism) |
| 59 | Huntington's disease |
| 59 | Animal |
| 58 | Levodopa (administration & dosage) |
| 58 | DNA Mutational Analysis |
| 57 | Tremor (physiopathology) |
| 57 | Prognosis |
| 57 | Longitudinal Studies |
| 56 | Prospective Studies |
| 56 | Mutation (genetics) |
| 56 | History, 20th Century |
| 56 | Dystonia (physiopathology) |
| 56 | Dyskinesia, Drug-Induced (etiology) |
| 55 | Huntington Disease (genetics) |
| 54 | United States |
| 54 | Psychiatric Status Rating Scales |
| 54 | Chorea |
| 53 | parkinsonism |
| 53 | Nuclear magnetic resonance imaging |
| 53 | Movement Disorders (diagnosis) |
| 53 | Genetic Predisposition to Disease |
| 53 | Cognition Disorders (diagnosis) |
| 52 | epidemiology |
| 52 | Magnetic Resonance Imaging (methods) |
| 52 | Dopamine (metabolism) |
| 51 | Evolution |
| 51 | Cross-Sectional Studies |
| 50 | Movement Disorders (etiology) |
| 50 | Gilles de la Tourette syndrome |
| 50 | Essential |
| 49 | Restless legs syndrome |
| 49 | Quality of Life |
| 49 | Pedigree |
| 49 | Pathophysiology |
| 49 | Clinical trial |
| 48 | levodopa |
| 48 | Psychometrics |
| 48 | Dominance, Cerebral (physiology) |
| 47 | Psychomotor Performance (physiology) |
| 46 | depression |
| 45 | genetics |
| 45 | Injections, Intramuscular |
| 45 | Evaluation scale |
| 44 | Movement Disorders (physiopathology) |
| 44 | Antipsychotic Agents (adverse effects) |
| 43 | Posture |
| 43 | Pilot Projects |
| 43 | Parkinson Disease (surgery) |
| 43 | Family Health |
| 43 | Basal ganglion |
| 43 | Activities of Daily Living |
| 42 | Subthalamic nucleus |
| 42 | Protein-Serine-Threonine Kinases (genetics) |
| 42 | Electroencephalography |
| 42 | Elderly |
| 42 | Dystonia (etiology) |
| 41 | Statistics, Nonparametric |
| 41 | Essential Tremor (physiopathology) |
| 41 | Dystonia (genetics) |
| 41 | Cognition |
| 40 | Point Mutation (genetics) |
| 40 | Incidence |
| 40 | Bontoxilysin |
| 40 | Ataxia |
| 39 | tremor |
| 39 | Pathogenesis |
| 39 | Huntington Disease (diagnosis) |
| 39 | Functional Laterality |
| 39 | Essential Tremor (diagnosis) |
| 39 | Dystonia (drug therapy) |
| 39 | Dyskinesia, Drug-Induced (diagnosis) |
| 39 | Carbidopa (therapeutic use) |
| 39 | Atrophy |
| 39 | Antipsychotic Agents (therapeutic use) |
| 38 | Video recording |
| 38 | Tremor (etiology) |
| 38 | Nerve Tissue Proteins (genetics) |
| 38 | Involuntary movement |
| 38 | Brain (metabolism) |
| 37 | Rats |
| 37 | Mental Status Schedule |
| 37 | Cognitive disorder |
| 36 | Tic |
| 36 | Substantia Nigra (pathology) |
| 36 | Sensitivity and Specificity |
| 36 | Multiple system atrophy |
| 36 | Genetic Predisposition to Disease (genetics) |
| 36 | Dopamine agonist |
| 36 | Carbidopa (administration & dosage) |
| 36 | Brain (physiopathology) |
| 35 | dementia |
| 35 | Reference Values |
| 35 | Parkinsonian Disorders (genetics) |
| 35 | Neuroleptic |
| 35 | Dyskinesia, Drug-Induced (drug therapy) |
| 35 | Animal model |
| 34 | Toxin |
| 34 | Sex Factors |
| 34 | Quality of life |
| 34 | Predictive Value of Tests |
| 33 | alpha-Synuclein (genetics) |
| 33 | Parkinsonian Disorders (diagnosis) |
| 33 | Parkinson Disease, Secondary (chemically induced) |
| 33 | Hand |
| 33 | Differential diagnostic |
| 33 | Botulinum Toxins, Type A (therapeutic use) |
| 32 | Neurons (pathology) |
| 32 | Motor Activity (physiology) |
| 32 | Mice |
| 32 | Huntington Disease (complications) |
| 32 | Emission tomography |
| 32 | Drug Combinations |
| 32 | Dopamine Agonists (therapeutic use) |
| 32 | Carbidopa (adverse effects) |
| 31 | Torticollis (drug therapy) |
| 31 | Tomography, X-Ray Computed |
| 31 | Motor control |
| 31 | History, 19th Century |
| 31 | Gene Frequency |
| 31 | Essential Tremor (epidemiology) |
| 31 | Alleles |
| 30 | dyskinesia |
| 30 | Risk |
| 30 | Odds Ratio |
| 30 | Muscle, Skeletal (physiopathology) |
| 30 | Long term |
| 30 | Huntington Disease (physiopathology) |
| 30 | Functional Laterality (physiology) |
| 30 | Essential tremor |
| 30 | Degeneration |
| 30 | Comorbidity |
| 29 | Tremor (drug therapy) |
| 29 | Parkinsonian Disorders (physiopathology) |
| 29 | Dystonic Disorders (diagnosis) |
| 29 | Cerebral Cortex (pathology) |
| 29 | Cerebellum |
| 28 | Ubiquitin-Protein Ligases (genetics) |
| 28 | Thalamus |
| 28 | Statistics as Topic |
| 28 | Regression Analysis |
| 28 | Parkinson Disease (radionuclide imaging) |
| 28 | Motor Skills (drug effects) |
| 28 | Medical screening |
| 28 | Etiology |
| 28 | Cerebral Cortex (physiopathology) |
| 28 | Botulinum Toxins (therapeutic use) |
| 28 | Blepharospasm |
| 27 | Positron emission tomography |
| 27 | Placebo |
| 27 | Neuroprotective Agents (therapeutic use) |
| 27 | Image Processing, Computer-Assisted |
| 27 | Family study |
| 27 | Electrodes, Implanted |
| 27 | Corpus Striatum (pathology) |
| 27 | Biomechanical Phenomena |
| 26 | restless legs syndrome |
| 26 | ataxia |
| 26 | alpha-Synuclein (metabolism) |
| 26 | Walking |
| 26 | Torticollis (diagnosis) |
| 26 | Psychosis |
| 26 | Parkinsonian Disorders (drug therapy) |
| 26 | Movement Disorders (drug therapy) |
| 26 | Genetic Testing |
| 26 | Clinical Trials as Topic |
| 25 | United States (epidemiology) |
| 25 | Tremor (genetics) |
| 25 | Neuromuscular Agents (therapeutic use) |
| 25 | Movement (physiology) |
| 25 | Infant |
| 25 | Idiopathic |
| 25 | Encephalon |
| 25 | Electromyography (methods) |
| 25 | Dementia (diagnosis) |
| 25 | Dementia (complications) |
| 25 | Corpus Striatum (metabolism) |
| 25 | Anticonvulsants (therapeutic use) |
| 25 | Agonist |
| 25 | Age of onset |
| 24 | subthalamic nucleus |
| 24 | basal ganglia |
| 24 | Questionnaire |
| 24 | Postural Balance (physiology) |
| 24 | Parkinsonian Disorders (pathology) |
| 24 | Neurons (physiology) |
| 24 | Neurons (metabolism) |
| 24 | History, 21st Century |
| 24 | Handwriting |
| 24 | Dystonic Disorders (genetics) |
| 24 | Dopamine Agents (therapeutic use) |
| 24 | Demography |
| 24 | Deep Brain Stimulation |
| 24 | Botulinum Toxins (administration & dosage) |
| 24 | Anxiety |
| 23 | Syndrome |
| 23 | Reaction Time (physiology) |
| 23 | Polymorphism, Single Nucleotide (genetics) |
| 23 | Pathology |
| 23 | Parkinson Disease (blood) |
| 23 | Observer Variation |
| 23 | Lewy body |
| 23 | Exons (genetics) |
| 23 | Dystonia (complications) |
| 23 | Cross-Over Studies |
| 23 | Confidence Intervals |
| 23 | Chorea (etiology) |
| 23 | Brain (drug effects) |
| 23 | Basal Ganglia (pathology) |
| 22 | quality of life |
| 22 | cognition |
| 22 | chorea |
| 22 | botulinum toxin |
| 22 | Trinucleotide Repeat Expansion (genetics) |
| 22 | Restless Legs Syndrome (diagnosis) |
| 22 | Psychomotor Performance |
| 22 | Proportional Hazards Models |
| 22 | Movement |
| 22 | Movement Disorders (therapy) |
| 22 | Lewy Bodies (pathology) |
| 22 | Gait |
| 22 | Essential Tremor (pathology) |
| 22 | Dystonic Disorders (physiopathology) |
| 22 | Chi-Square Distribution |
| 22 | Cerebellum (pathology) |
| 22 | Botulinum Toxins, Type A (administration & dosage) |
| 21 | treatment |
| 21 | multiple system atrophy |
| 21 | dopamine |
| 21 | UPDRS |
| 21 | Tomography, Emission-Computed |
| 21 | Surgery |
| 21 | Subthalamic Nucleus (physiology) |
| 21 | Sleep |
| 21 | Receptors, Dopamine (drug effects) |
| 21 | Posture (physiology) |
| 21 | Positron-Emission Tomography |
| 21 | Movement Disorders (genetics) |
| 21 | Dystonia (therapy) |
| 21 | Dystonia (pathology) |
| 21 | Dopamine Agents (adverse effects) |
| 21 | Corpus Striatum (physiopathology) |
| 21 | Corpus Striatum (drug effects) |
| 21 | Clostridium botulinum |
| 21 | Case control study |
| 21 | Botulinum toxin |
| 21 | Anti-Dyskinesia Agents (therapeutic use) |
| 20 | gait |
| 20 | Unilateral |
| 20 | Tourette's syndrome |
| 20 | Tourette syndrome |
| 20 | Supranuclear ophthalmoplegia |
| 20 | Substantia Nigra (drug effects) |
| 20 | Review |
| 20 | Receptors, Dopamine (physiology) |
| 20 | Neurologic Examination (statistics & numerical data) |
| 20 | Myoclonus (physiopathology) |
| 20 | Muscle, Skeletal (innervation) |
| 20 | Motor Skills (physiology) |
| 20 | Monkey |
| 20 | Huntington Disease (drug therapy) |
| 20 | Gait (physiology) |
| 20 | Fatal Outcome |
| 20 | Essential Tremor (genetics) |
| 20 | Dopamine Agonists (adverse effects) |
| 20 | Depression (etiology) |
| 20 | Deep Brain Stimulation (adverse effects) |
| 20 | Clozapine |
| 20 | Alzheimer disease |
| 19 | rating scales |
| 19 | Validity |
| 19 | Tremor (therapy) |
| 19 | Torticollis (physiopathology) |
| 19 | Supranuclear Palsy, Progressive (diagnosis) |
| 19 | Stereotaxic Techniques |
| 19 | Serotonin |
| 19 | Psychogenic |
| 19 | Parkinson Disease (mortality) |
| 19 | Myoclonus (drug therapy) |
| 19 | Movement Disorders (history) |
| 19 | Movement Disorders (complications) |
| 19 | Logistic Models |
| 19 | Globus Pallidus (surgery) |
| 19 | Globus Pallidus (physiopathology) |
| 19 | Genetics |
| 19 | Essential Tremor (drug therapy) |
| 19 | Double blind study |
| 19 | Cognition (physiology) |
| 19 | Basal Ganglia (physiopathology) |
| 19 | Activities of Daily Living (classification) |
| 18 | movement disorders |
| 18 | Trinucleotide Repeats (genetics) |
| 18 | Tourette Syndrome (physiopathology) |
| 18 | Tomography, Emission-Computed, Single-Photon |
| 18 | Restless Legs Syndrome (physiopathology) |
| 18 | Putamen (pathology) |
| 18 | Parkinsonian Disorders (complications) |
| 18 | Parkinson Disease (classification) |
| 18 | Motor Activity (drug effects) |
| 18 | Mitochondria |
| 18 | Dystonic Disorders (etiology) |
| 18 | Dystonia (chemically induced) |
| 18 | Dyskinesia, Drug-Induced (physiopathology) |
| 18 | Disability |
| 18 | Carbidopa |
| 18 | Brain (vertebrata) |
| 18 | Brain (radionuclide imaging) |
| 18 | Autopsy |
| 18 | Alzheimer's disease |
| 17 | neurodegeneration |
| 17 | myoclonus |
| 17 | cerebellum |
| 17 | anxiety |
| 17 | Tremor (epidemiology) |
| 17 | Tourette Syndrome (drug therapy) |
| 17 | Substantia Nigra (physiopathology) |
| 17 | Spinocerebellar ataxia |
| 17 | Sleep disorder |
| 17 | Reliability |
| 17 | Psychotropic |
| 17 | Polysomnography |
| 17 | Polymorphism |
| 17 | Polymerase Chain Reaction |
| 17 | Parkinsonian Disorders (epidemiology) |
| 17 | Parkinson Disease (history) |
| 17 | Olfaction |
| 17 | Nuclear Proteins (genetics) |
| 17 | Neurons (drug effects) |
| 17 | Music |
| 17 | Lewy body dementia |
| 17 | Levodopa (pharmacokinetics) |
| 17 | Late |
| 17 | LRRK2 |
| 17 | Huntington Disease (pathology) |
| 17 | Hand (physiopathology) |
| 17 | Gait Disorders, Neurologic (etiology) |
| 17 | Fluctuations |
| 17 | Evaluation |
| 17 | Dyskinesias (etiology) |
| 17 | Dementia (etiology) |
| 17 | D2 Dopamine receptor |
| 17 | Corpus Striatum (radionuclide imaging) |
| 16 | bradykinesia |
| 16 | Validation |
| 16 | Tourette Syndrome (diagnosis) |
| 16 | Torticollis |
| 16 | Smoking (epidemiology) |
| 16 | Recommendation |
| 16 | Rat |
| 16 | Psychotic Disorders (drug therapy) |
| 16 | Polymorphism, Genetic (genetics) |
| 16 | Parkinson Disease, Secondary (diagnosis) |
| 16 | Parkinson Disease (economics) |
| 16 | Parkin |
| 16 | Pain |
| 16 | Outcome Assessment (Health Care) |
| 16 | Neurologic Examination (methods) |
| 16 | Motor Neurons (physiology) |
| 16 | MPTP |
| 16 | Hypokinesia (etiology) |
| 16 | Databases, Factual (statistics & numerical data) |
| 16 | Cognition Disorders (psychology) |
| 16 | Cognition Disorders (epidemiology) |
| 16 | Chorea (genetics) |
| 16 | Chorea (diagnosis) |
| 16 | Behavior |
| 15 | cervical dystonia |
| 15 | Tics |
| 15 | Spasmodic torticollis |
| 15 | Signal Processing, Computer-Assisted |
| 15 | Selegiline (therapeutic use) |
| 15 | Safety |
| 15 | Parkinson Disease, Secondary (physiopathology) |
| 15 | Parkinson Disease (rehabilitation) |
| 15 | PET |
| 15 | Neuron |
| 15 | Nerve Degeneration (pathology) |
| 15 | Movement (drug effects) |
| 15 | Mouse |
| 15 | Motor Cortex (physiopathology) |
| 15 | Kinematics |
| 15 | Health Surveys |
| 15 | Hallucination |
| 15 | Globus Pallidus (pathology) |
| 15 | Genetic determinism |
| 15 | Evoked Potentials, Motor (physiology) |
| 15 | Encephalitis |
| 15 | Electromyography (drug effects) |
| 15 | Dystonic Disorders (pathology) |
| 15 | Dopamine receptor |
| 15 | Degenerative disease |
| 15 | Caudate Nucleus (pathology) |
| 15 | Basal Ganglia Diseases (diagnosis) |
| 15 | Atrophy (pathology) |
| 15 | Antipsychotic |
| 15 | Antiparkinson Agents (pharmacokinetics) |
| 14 | progressive supranuclear palsy |
| 14 | clinical trial |
| 14 | Writer cramp |
| 14 | Video Recording |
| 14 | Terminology as Topic |
| 14 | Supranuclear Palsy, Progressive (physiopathology) |
| 14 | Subthalamic Nucleus (physiopathology) |
| 14 | Spinocerebellar Degenerations (genetics) |
| 14 | Spasticity |
| 14 | Restless Legs Syndrome (drug therapy) |
| 14 | ROC Curve |
